nodes	percent_of_prediction	percent_of_DWPC	metapath
Temozolomide—Alkylating Activity—Altretamine—ovarian cancer	0.401	0.465	CiPCiCtD
Temozolomide—Alkylating Activity—Melphalan—ovarian cancer	0.23	0.267	CiPCiCtD
Temozolomide—Alkylating Activity—Chlorambucil—ovarian cancer	0.23	0.267	CiPCiCtD
Temozolomide—CYP3A4—Topotecan—ovarian cancer	0.0172	0.354	CbGbCtD
Temozolomide—CYP3A4—Vinorelbine—ovarian cancer	0.0121	0.249	CbGbCtD
Temozolomide—CYP3A4—Paclitaxel—ovarian cancer	0.00853	0.175	CbGbCtD
Temozolomide—CYP3A4—Docetaxel—ovarian cancer	0.00617	0.127	CbGbCtD
Temozolomide—CYP3A4—Doxorubicin—ovarian cancer	0.0046	0.0945	CbGbCtD
Temozolomide—Weight decreased—Epirubicin—ovarian cancer	3.91e-05	0.000433	CcSEcCtD
Temozolomide—Hyperglycaemia—Epirubicin—ovarian cancer	3.9e-05	0.000432	CcSEcCtD
Temozolomide—Cough—Docetaxel—ovarian cancer	3.9e-05	0.000432	CcSEcCtD
Temozolomide—Insomnia—Paclitaxel—ovarian cancer	3.89e-05	0.000431	CcSEcCtD
Temozolomide—Pneumonia—Epirubicin—ovarian cancer	3.88e-05	0.000429	CcSEcCtD
Temozolomide—Convulsion—Docetaxel—ovarian cancer	3.87e-05	0.000429	CcSEcCtD
Temozolomide—Paraesthesia—Paclitaxel—ovarian cancer	3.86e-05	0.000428	CcSEcCtD
Temozolomide—Hypertension—Docetaxel—ovarian cancer	3.85e-05	0.000427	CcSEcCtD
Temozolomide—Infestation NOS—Epirubicin—ovarian cancer	3.85e-05	0.000427	CcSEcCtD
Temozolomide—Infestation—Epirubicin—ovarian cancer	3.85e-05	0.000427	CcSEcCtD
Temozolomide—Bronchitis—Doxorubicin—ovarian cancer	3.85e-05	0.000426	CcSEcCtD
Temozolomide—Dyspnoea—Paclitaxel—ovarian cancer	3.83e-05	0.000425	CcSEcCtD
Temozolomide—Somnolence—Paclitaxel—ovarian cancer	3.82e-05	0.000423	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	3.82e-05	0.000423	CcSEcCtD
Temozolomide—Arthralgia—Docetaxel—ovarian cancer	3.8e-05	0.000421	CcSEcCtD
Temozolomide—Myalgia—Docetaxel—ovarian cancer	3.8e-05	0.000421	CcSEcCtD
Temozolomide—Pancytopenia—Doxorubicin—ovarian cancer	3.8e-05	0.000421	CcSEcCtD
Temozolomide—Nausea—Vinorelbine—ovarian cancer	3.8e-05	0.000421	CcSEcCtD
Temozolomide—Dyspepsia—Paclitaxel—ovarian cancer	3.78e-05	0.000419	CcSEcCtD
Temozolomide—Neuropathy peripheral—Epirubicin—ovarian cancer	3.78e-05	0.000419	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	3.77e-05	0.000418	CcSEcCtD
Temozolomide—Stomatitis—Epirubicin—ovarian cancer	3.76e-05	0.000416	CcSEcCtD
Temozolomide—Urinary tract infection—Epirubicin—ovarian cancer	3.75e-05	0.000415	CcSEcCtD
Temozolomide—Dysuria—Doxorubicin—ovarian cancer	3.74e-05	0.000414	CcSEcCtD
Temozolomide—Neutropenia—Doxorubicin—ovarian cancer	3.74e-05	0.000414	CcSEcCtD
Temozolomide—Decreased appetite—Paclitaxel—ovarian cancer	3.74e-05	0.000414	CcSEcCtD
Temozolomide—Dry mouth—Docetaxel—ovarian cancer	3.72e-05	0.000412	CcSEcCtD
Temozolomide—Upper respiratory tract infection—Doxorubicin—ovarian cancer	3.72e-05	0.000412	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Paclitaxel—ovarian cancer	3.71e-05	0.000411	CcSEcCtD
Temozolomide—Fatigue—Paclitaxel—ovarian cancer	3.71e-05	0.000411	CcSEcCtD
Temozolomide—Pollakiuria—Doxorubicin—ovarian cancer	3.69e-05	0.000409	CcSEcCtD
Temozolomide—Pain—Paclitaxel—ovarian cancer	3.68e-05	0.000407	CcSEcCtD
Temozolomide—Constipation—Paclitaxel—ovarian cancer	3.68e-05	0.000407	CcSEcCtD
Temozolomide—Confusional state—Docetaxel—ovarian cancer	3.67e-05	0.000407	CcSEcCtD
Temozolomide—Photosensitivity reaction—Doxorubicin—ovarian cancer	3.65e-05	0.000404	CcSEcCtD
Temozolomide—Hepatobiliary disease—Epirubicin—ovarian cancer	3.64e-05	0.000404	CcSEcCtD
Temozolomide—Oedema—Docetaxel—ovarian cancer	3.64e-05	0.000404	CcSEcCtD
Temozolomide—Anaphylactic shock—Docetaxel—ovarian cancer	3.64e-05	0.000404	CcSEcCtD
Temozolomide—Weight increased—Doxorubicin—ovarian cancer	3.64e-05	0.000403	CcSEcCtD
Temozolomide—Infection—Docetaxel—ovarian cancer	3.62e-05	0.000401	CcSEcCtD
Temozolomide—Weight decreased—Doxorubicin—ovarian cancer	3.62e-05	0.000401	CcSEcCtD
Temozolomide—Sinusitis—Epirubicin—ovarian cancer	3.61e-05	0.000401	CcSEcCtD
Temozolomide—Hyperglycaemia—Doxorubicin—ovarian cancer	3.61e-05	0.0004	CcSEcCtD
Temozolomide—Pneumonia—Doxorubicin—ovarian cancer	3.59e-05	0.000397	CcSEcCtD
Temozolomide—Nervous system disorder—Docetaxel—ovarian cancer	3.57e-05	0.000396	CcSEcCtD
Temozolomide—Thrombocytopenia—Docetaxel—ovarian cancer	3.57e-05	0.000395	CcSEcCtD
Temozolomide—Infestation NOS—Doxorubicin—ovarian cancer	3.57e-05	0.000395	CcSEcCtD
Temozolomide—Infestation—Doxorubicin—ovarian cancer	3.57e-05	0.000395	CcSEcCtD
Temozolomide—Feeling abnormal—Paclitaxel—ovarian cancer	3.54e-05	0.000393	CcSEcCtD
Temozolomide—Skin disorder—Docetaxel—ovarian cancer	3.54e-05	0.000392	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	3.53e-05	0.000392	CcSEcCtD
Temozolomide—Gastrointestinal pain—Paclitaxel—ovarian cancer	3.51e-05	0.000389	CcSEcCtD
Temozolomide—Neuropathy peripheral—Doxorubicin—ovarian cancer	3.49e-05	0.000387	CcSEcCtD
Temozolomide—Haemoglobin—Epirubicin—ovarian cancer	3.48e-05	0.000385	CcSEcCtD
Temozolomide—Stomatitis—Doxorubicin—ovarian cancer	3.48e-05	0.000385	CcSEcCtD
Temozolomide—Anorexia—Docetaxel—ovarian cancer	3.47e-05	0.000385	CcSEcCtD
Temozolomide—Urinary tract infection—Doxorubicin—ovarian cancer	3.47e-05	0.000384	CcSEcCtD
Temozolomide—Haemorrhage—Epirubicin—ovarian cancer	3.46e-05	0.000383	CcSEcCtD
Temozolomide—Hepatitis—Epirubicin—ovarian cancer	3.46e-05	0.000383	CcSEcCtD
Temozolomide—Hypoaesthesia—Epirubicin—ovarian cancer	3.44e-05	0.000381	CcSEcCtD
Temozolomide—Pharyngitis—Epirubicin—ovarian cancer	3.43e-05	0.00038	CcSEcCtD
Temozolomide—Urinary tract disorder—Epirubicin—ovarian cancer	3.42e-05	0.000379	CcSEcCtD
Temozolomide—Urticaria—Paclitaxel—ovarian cancer	3.41e-05	0.000378	CcSEcCtD
Temozolomide—Oedema peripheral—Epirubicin—ovarian cancer	3.41e-05	0.000378	CcSEcCtD
Temozolomide—Connective tissue disorder—Epirubicin—ovarian cancer	3.4e-05	0.000377	CcSEcCtD
Temozolomide—Body temperature increased—Paclitaxel—ovarian cancer	3.4e-05	0.000377	CcSEcCtD
Temozolomide—Abdominal pain—Paclitaxel—ovarian cancer	3.4e-05	0.000377	CcSEcCtD
Temozolomide—Urethral disorder—Epirubicin—ovarian cancer	3.39e-05	0.000376	CcSEcCtD
Temozolomide—Hepatobiliary disease—Doxorubicin—ovarian cancer	3.37e-05	0.000374	CcSEcCtD
Temozolomide—Sinusitis—Doxorubicin—ovarian cancer	3.34e-05	0.000371	CcSEcCtD
Temozolomide—Visual impairment—Epirubicin—ovarian cancer	3.33e-05	0.000369	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Docetaxel—ovarian cancer	3.32e-05	0.000368	CcSEcCtD
Temozolomide—Insomnia—Docetaxel—ovarian cancer	3.3e-05	0.000365	CcSEcCtD
Temozolomide—Paraesthesia—Docetaxel—ovarian cancer	3.27e-05	0.000363	CcSEcCtD
Temozolomide—Erythema multiforme—Epirubicin—ovarian cancer	3.27e-05	0.000362	CcSEcCtD
Temozolomide—Dyspnoea—Docetaxel—ovarian cancer	3.25e-05	0.00036	CcSEcCtD
Temozolomide—Somnolence—Docetaxel—ovarian cancer	3.24e-05	0.000359	CcSEcCtD
Temozolomide—Eye disorder—Epirubicin—ovarian cancer	3.23e-05	0.000358	CcSEcCtD
Temozolomide—Tinnitus—Epirubicin—ovarian cancer	3.22e-05	0.000357	CcSEcCtD
Temozolomide—Haemoglobin—Doxorubicin—ovarian cancer	3.22e-05	0.000356	CcSEcCtD
Temozolomide—Flushing—Epirubicin—ovarian cancer	3.21e-05	0.000356	CcSEcCtD
Temozolomide—Cardiac disorder—Epirubicin—ovarian cancer	3.21e-05	0.000356	CcSEcCtD
Temozolomide—Dyspepsia—Docetaxel—ovarian cancer	3.21e-05	0.000355	CcSEcCtD
Temozolomide—Hepatitis—Doxorubicin—ovarian cancer	3.2e-05	0.000355	CcSEcCtD
Temozolomide—Haemorrhage—Doxorubicin—ovarian cancer	3.2e-05	0.000355	CcSEcCtD
Temozolomide—Hypoaesthesia—Doxorubicin—ovarian cancer	3.18e-05	0.000353	CcSEcCtD
Temozolomide—Pharyngitis—Doxorubicin—ovarian cancer	3.18e-05	0.000352	CcSEcCtD
Temozolomide—Decreased appetite—Docetaxel—ovarian cancer	3.17e-05	0.000351	CcSEcCtD
Temozolomide—Hypersensitivity—Paclitaxel—ovarian cancer	3.17e-05	0.000351	CcSEcCtD
Temozolomide—Urinary tract disorder—Doxorubicin—ovarian cancer	3.16e-05	0.00035	CcSEcCtD
Temozolomide—Oedema peripheral—Doxorubicin—ovarian cancer	3.15e-05	0.000349	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Docetaxel—ovarian cancer	3.15e-05	0.000349	CcSEcCtD
Temozolomide—Connective tissue disorder—Doxorubicin—ovarian cancer	3.14e-05	0.000348	CcSEcCtD
Temozolomide—Fatigue—Docetaxel—ovarian cancer	3.14e-05	0.000348	CcSEcCtD
Temozolomide—Angiopathy—Epirubicin—ovarian cancer	3.14e-05	0.000348	CcSEcCtD
Temozolomide—Urethral disorder—Doxorubicin—ovarian cancer	3.14e-05	0.000348	CcSEcCtD
Temozolomide—Immune system disorder—Epirubicin—ovarian cancer	3.12e-05	0.000346	CcSEcCtD
Temozolomide—Mediastinal disorder—Epirubicin—ovarian cancer	3.12e-05	0.000345	CcSEcCtD
Temozolomide—Pain—Docetaxel—ovarian cancer	3.12e-05	0.000345	CcSEcCtD
Temozolomide—Constipation—Docetaxel—ovarian cancer	3.12e-05	0.000345	CcSEcCtD
Temozolomide—Chills—Epirubicin—ovarian cancer	3.1e-05	0.000344	CcSEcCtD
Temozolomide—Visual impairment—Doxorubicin—ovarian cancer	3.08e-05	0.000342	CcSEcCtD
Temozolomide—Asthenia—Paclitaxel—ovarian cancer	3.08e-05	0.000342	CcSEcCtD
Temozolomide—Alopecia—Epirubicin—ovarian cancer	3.06e-05	0.000339	CcSEcCtD
Temozolomide—Pruritus—Paclitaxel—ovarian cancer	3.04e-05	0.000337	CcSEcCtD
Temozolomide—Mental disorder—Epirubicin—ovarian cancer	3.03e-05	0.000336	CcSEcCtD
Temozolomide—Erythema multiforme—Doxorubicin—ovarian cancer	3.03e-05	0.000335	CcSEcCtD
Temozolomide—Malnutrition—Epirubicin—ovarian cancer	3.01e-05	0.000334	CcSEcCtD
Temozolomide—Erythema—Epirubicin—ovarian cancer	3.01e-05	0.000334	CcSEcCtD
Temozolomide—Feeling abnormal—Docetaxel—ovarian cancer	3e-05	0.000333	CcSEcCtD
Temozolomide—Eye disorder—Doxorubicin—ovarian cancer	2.99e-05	0.000331	CcSEcCtD
Temozolomide—Tinnitus—Doxorubicin—ovarian cancer	2.98e-05	0.000331	CcSEcCtD
Temozolomide—Gastrointestinal pain—Docetaxel—ovarian cancer	2.98e-05	0.00033	CcSEcCtD
Temozolomide—Flushing—Doxorubicin—ovarian cancer	2.97e-05	0.000329	CcSEcCtD
Temozolomide—Cardiac disorder—Doxorubicin—ovarian cancer	2.97e-05	0.000329	CcSEcCtD
Temozolomide—Dysgeusia—Epirubicin—ovarian cancer	2.95e-05	0.000327	CcSEcCtD
Temozolomide—Diarrhoea—Paclitaxel—ovarian cancer	2.94e-05	0.000326	CcSEcCtD
Temozolomide—Back pain—Epirubicin—ovarian cancer	2.91e-05	0.000323	CcSEcCtD
Temozolomide—Angiopathy—Doxorubicin—ovarian cancer	2.9e-05	0.000322	CcSEcCtD
Temozolomide—Immune system disorder—Doxorubicin—ovarian cancer	2.89e-05	0.00032	CcSEcCtD
Temozolomide—Mediastinal disorder—Doxorubicin—ovarian cancer	2.88e-05	0.00032	CcSEcCtD
Temozolomide—Body temperature increased—Docetaxel—ovarian cancer	2.88e-05	0.000319	CcSEcCtD
Temozolomide—Abdominal pain—Docetaxel—ovarian cancer	2.88e-05	0.000319	CcSEcCtD
Temozolomide—Chills—Doxorubicin—ovarian cancer	2.87e-05	0.000318	CcSEcCtD
Temozolomide—Dizziness—Paclitaxel—ovarian cancer	2.84e-05	0.000315	CcSEcCtD
Temozolomide—Vision blurred—Epirubicin—ovarian cancer	2.84e-05	0.000314	CcSEcCtD
Temozolomide—Alopecia—Doxorubicin—ovarian cancer	2.83e-05	0.000313	CcSEcCtD
Temozolomide—Mental disorder—Doxorubicin—ovarian cancer	2.8e-05	0.000311	CcSEcCtD
Temozolomide—Ill-defined disorder—Epirubicin—ovarian cancer	2.79e-05	0.00031	CcSEcCtD
Temozolomide—Malnutrition—Doxorubicin—ovarian cancer	2.79e-05	0.000309	CcSEcCtD
Temozolomide—Erythema—Doxorubicin—ovarian cancer	2.79e-05	0.000309	CcSEcCtD
Temozolomide—Anaemia—Epirubicin—ovarian cancer	2.78e-05	0.000308	CcSEcCtD
Temozolomide—Agitation—Epirubicin—ovarian cancer	2.77e-05	0.000307	CcSEcCtD
Temozolomide—Vomiting—Paclitaxel—ovarian cancer	2.73e-05	0.000303	CcSEcCtD
Temozolomide—Dysgeusia—Doxorubicin—ovarian cancer	2.73e-05	0.000302	CcSEcCtD
Temozolomide—Malaise—Epirubicin—ovarian cancer	2.72e-05	0.000301	CcSEcCtD
Temozolomide—Rash—Paclitaxel—ovarian cancer	2.71e-05	0.0003	CcSEcCtD
Temozolomide—Dermatitis—Paclitaxel—ovarian cancer	2.71e-05	0.0003	CcSEcCtD
Temozolomide—Vertigo—Epirubicin—ovarian cancer	2.71e-05	0.0003	CcSEcCtD
Temozolomide—Leukopenia—Epirubicin—ovarian cancer	2.7e-05	0.000299	CcSEcCtD
Temozolomide—Back pain—Doxorubicin—ovarian cancer	2.69e-05	0.000299	CcSEcCtD
Temozolomide—Headache—Paclitaxel—ovarian cancer	2.69e-05	0.000298	CcSEcCtD
Temozolomide—Hypersensitivity—Docetaxel—ovarian cancer	2.68e-05	0.000297	CcSEcCtD
Temozolomide—Palpitations—Epirubicin—ovarian cancer	2.66e-05	0.000295	CcSEcCtD
Temozolomide—Cough—Epirubicin—ovarian cancer	2.63e-05	0.000291	CcSEcCtD
Temozolomide—Vision blurred—Doxorubicin—ovarian cancer	2.63e-05	0.000291	CcSEcCtD
Temozolomide—Asthenia—Docetaxel—ovarian cancer	2.61e-05	0.00029	CcSEcCtD
Temozolomide—Convulsion—Epirubicin—ovarian cancer	2.61e-05	0.000289	CcSEcCtD
Temozolomide—Hypertension—Epirubicin—ovarian cancer	2.6e-05	0.000288	CcSEcCtD
Temozolomide—Ill-defined disorder—Doxorubicin—ovarian cancer	2.58e-05	0.000286	CcSEcCtD
Temozolomide—Pruritus—Docetaxel—ovarian cancer	2.58e-05	0.000286	CcSEcCtD
Temozolomide—Anaemia—Doxorubicin—ovarian cancer	2.57e-05	0.000285	CcSEcCtD
Temozolomide—Arthralgia—Epirubicin—ovarian cancer	2.56e-05	0.000284	CcSEcCtD
Temozolomide—Myalgia—Epirubicin—ovarian cancer	2.56e-05	0.000284	CcSEcCtD
Temozolomide—Agitation—Doxorubicin—ovarian cancer	2.56e-05	0.000284	CcSEcCtD
Temozolomide—Anxiety—Epirubicin—ovarian cancer	2.55e-05	0.000283	CcSEcCtD
Temozolomide—Nausea—Paclitaxel—ovarian cancer	2.55e-05	0.000283	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	2.55e-05	0.000282	CcSEcCtD
Temozolomide—Discomfort—Epirubicin—ovarian cancer	2.53e-05	0.000281	CcSEcCtD
Temozolomide—Malaise—Doxorubicin—ovarian cancer	2.51e-05	0.000278	CcSEcCtD
Temozolomide—Dry mouth—Epirubicin—ovarian cancer	2.51e-05	0.000278	CcSEcCtD
Temozolomide—Vertigo—Doxorubicin—ovarian cancer	2.5e-05	0.000277	CcSEcCtD
Temozolomide—Leukopenia—Doxorubicin—ovarian cancer	2.49e-05	0.000276	CcSEcCtD
Temozolomide—Diarrhoea—Docetaxel—ovarian cancer	2.49e-05	0.000276	CcSEcCtD
Temozolomide—Confusional state—Epirubicin—ovarian cancer	2.48e-05	0.000275	CcSEcCtD
Temozolomide—Palpitations—Doxorubicin—ovarian cancer	2.46e-05	0.000273	CcSEcCtD
Temozolomide—Oedema—Epirubicin—ovarian cancer	2.46e-05	0.000272	CcSEcCtD
Temozolomide—Anaphylactic shock—Epirubicin—ovarian cancer	2.46e-05	0.000272	CcSEcCtD
Temozolomide—Infection—Epirubicin—ovarian cancer	2.44e-05	0.000271	CcSEcCtD
Temozolomide—Cough—Doxorubicin—ovarian cancer	2.43e-05	0.000269	CcSEcCtD
Temozolomide—Convulsion—Doxorubicin—ovarian cancer	2.41e-05	0.000267	CcSEcCtD
Temozolomide—Nervous system disorder—Epirubicin—ovarian cancer	2.41e-05	0.000267	CcSEcCtD
Temozolomide—Dizziness—Docetaxel—ovarian cancer	2.41e-05	0.000267	CcSEcCtD
Temozolomide—Thrombocytopenia—Epirubicin—ovarian cancer	2.41e-05	0.000267	CcSEcCtD
Temozolomide—Hypertension—Doxorubicin—ovarian cancer	2.41e-05	0.000267	CcSEcCtD
Temozolomide—Skin disorder—Epirubicin—ovarian cancer	2.39e-05	0.000264	CcSEcCtD
Temozolomide—Hyperhidrosis—Epirubicin—ovarian cancer	2.38e-05	0.000263	CcSEcCtD
Temozolomide—Arthralgia—Doxorubicin—ovarian cancer	2.37e-05	0.000263	CcSEcCtD
Temozolomide—Myalgia—Doxorubicin—ovarian cancer	2.37e-05	0.000263	CcSEcCtD
Temozolomide—Anxiety—Doxorubicin—ovarian cancer	2.36e-05	0.000262	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	2.36e-05	0.000261	CcSEcCtD
Temozolomide—Discomfort—Doxorubicin—ovarian cancer	2.34e-05	0.00026	CcSEcCtD
Temozolomide—Anorexia—Epirubicin—ovarian cancer	2.34e-05	0.00026	CcSEcCtD
Temozolomide—Dry mouth—Doxorubicin—ovarian cancer	2.32e-05	0.000257	CcSEcCtD
Temozolomide—Vomiting—Docetaxel—ovarian cancer	2.32e-05	0.000257	CcSEcCtD
Temozolomide—Rash—Docetaxel—ovarian cancer	2.3e-05	0.000255	CcSEcCtD
Temozolomide—Dermatitis—Docetaxel—ovarian cancer	2.3e-05	0.000254	CcSEcCtD
Temozolomide—Confusional state—Doxorubicin—ovarian cancer	2.29e-05	0.000254	CcSEcCtD
Temozolomide—Headache—Docetaxel—ovarian cancer	2.28e-05	0.000253	CcSEcCtD
Temozolomide—Anaphylactic shock—Doxorubicin—ovarian cancer	2.27e-05	0.000252	CcSEcCtD
Temozolomide—Oedema—Doxorubicin—ovarian cancer	2.27e-05	0.000252	CcSEcCtD
Temozolomide—Infection—Doxorubicin—ovarian cancer	2.26e-05	0.00025	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Epirubicin—ovarian cancer	2.24e-05	0.000248	CcSEcCtD
Temozolomide—Nervous system disorder—Doxorubicin—ovarian cancer	2.23e-05	0.000247	CcSEcCtD
Temozolomide—Thrombocytopenia—Doxorubicin—ovarian cancer	2.23e-05	0.000247	CcSEcCtD
Temozolomide—Insomnia—Epirubicin—ovarian cancer	2.22e-05	0.000246	CcSEcCtD
Temozolomide—Skin disorder—Doxorubicin—ovarian cancer	2.21e-05	0.000245	CcSEcCtD
Temozolomide—Paraesthesia—Epirubicin—ovarian cancer	2.21e-05	0.000245	CcSEcCtD
Temozolomide—Hyperhidrosis—Doxorubicin—ovarian cancer	2.2e-05	0.000244	CcSEcCtD
Temozolomide—Dyspnoea—Epirubicin—ovarian cancer	2.19e-05	0.000243	CcSEcCtD
Temozolomide—Somnolence—Epirubicin—ovarian cancer	2.18e-05	0.000242	CcSEcCtD
Temozolomide—Anorexia—Doxorubicin—ovarian cancer	2.17e-05	0.00024	CcSEcCtD
Temozolomide—Nausea—Docetaxel—ovarian cancer	2.16e-05	0.00024	CcSEcCtD
Temozolomide—Dyspepsia—Epirubicin—ovarian cancer	2.16e-05	0.00024	CcSEcCtD
Temozolomide—Decreased appetite—Epirubicin—ovarian cancer	2.14e-05	0.000237	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Epirubicin—ovarian cancer	2.12e-05	0.000235	CcSEcCtD
Temozolomide—Fatigue—Epirubicin—ovarian cancer	2.12e-05	0.000235	CcSEcCtD
Temozolomide—Pain—Epirubicin—ovarian cancer	2.1e-05	0.000233	CcSEcCtD
Temozolomide—Constipation—Epirubicin—ovarian cancer	2.1e-05	0.000233	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	2.07e-05	0.00023	CcSEcCtD
Temozolomide—Insomnia—Doxorubicin—ovarian cancer	2.06e-05	0.000228	CcSEcCtD
Temozolomide—Paraesthesia—Doxorubicin—ovarian cancer	2.04e-05	0.000226	CcSEcCtD
Temozolomide—Dyspnoea—Doxorubicin—ovarian cancer	2.03e-05	0.000225	CcSEcCtD
Temozolomide—Feeling abnormal—Epirubicin—ovarian cancer	2.03e-05	0.000224	CcSEcCtD
Temozolomide—Somnolence—Doxorubicin—ovarian cancer	2.02e-05	0.000224	CcSEcCtD
Temozolomide—Gastrointestinal pain—Epirubicin—ovarian cancer	2.01e-05	0.000223	CcSEcCtD
Temozolomide—Dyspepsia—Doxorubicin—ovarian cancer	2e-05	0.000222	CcSEcCtD
Temozolomide—Decreased appetite—Doxorubicin—ovarian cancer	1.98e-05	0.000219	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Doxorubicin—ovarian cancer	1.96e-05	0.000218	CcSEcCtD
Temozolomide—Fatigue—Doxorubicin—ovarian cancer	1.96e-05	0.000217	CcSEcCtD
Temozolomide—Urticaria—Epirubicin—ovarian cancer	1.95e-05	0.000216	CcSEcCtD
Temozolomide—Pain—Doxorubicin—ovarian cancer	1.94e-05	0.000215	CcSEcCtD
Temozolomide—Constipation—Doxorubicin—ovarian cancer	1.94e-05	0.000215	CcSEcCtD
Temozolomide—Body temperature increased—Epirubicin—ovarian cancer	1.94e-05	0.000215	CcSEcCtD
Temozolomide—Abdominal pain—Epirubicin—ovarian cancer	1.94e-05	0.000215	CcSEcCtD
Temozolomide—Feeling abnormal—Doxorubicin—ovarian cancer	1.87e-05	0.000208	CcSEcCtD
Temozolomide—Gastrointestinal pain—Doxorubicin—ovarian cancer	1.86e-05	0.000206	CcSEcCtD
Temozolomide—Hypersensitivity—Epirubicin—ovarian cancer	1.81e-05	0.000201	CcSEcCtD
Temozolomide—Urticaria—Doxorubicin—ovarian cancer	1.81e-05	0.0002	CcSEcCtD
Temozolomide—Abdominal pain—Doxorubicin—ovarian cancer	1.8e-05	0.000199	CcSEcCtD
Temozolomide—Body temperature increased—Doxorubicin—ovarian cancer	1.8e-05	0.000199	CcSEcCtD
Temozolomide—Asthenia—Epirubicin—ovarian cancer	1.76e-05	0.000195	CcSEcCtD
Temozolomide—Pruritus—Epirubicin—ovarian cancer	1.74e-05	0.000193	CcSEcCtD
Temozolomide—Diarrhoea—Epirubicin—ovarian cancer	1.68e-05	0.000186	CcSEcCtD
Temozolomide—Hypersensitivity—Doxorubicin—ovarian cancer	1.68e-05	0.000186	CcSEcCtD
Temozolomide—Asthenia—Doxorubicin—ovarian cancer	1.63e-05	0.000181	CcSEcCtD
Temozolomide—Dizziness—Epirubicin—ovarian cancer	1.63e-05	0.00018	CcSEcCtD
Temozolomide—Pruritus—Doxorubicin—ovarian cancer	1.61e-05	0.000178	CcSEcCtD
Temozolomide—Vomiting—Epirubicin—ovarian cancer	1.56e-05	0.000173	CcSEcCtD
Temozolomide—Diarrhoea—Doxorubicin—ovarian cancer	1.56e-05	0.000172	CcSEcCtD
Temozolomide—Rash—Epirubicin—ovarian cancer	1.55e-05	0.000172	CcSEcCtD
Temozolomide—Dermatitis—Epirubicin—ovarian cancer	1.55e-05	0.000172	CcSEcCtD
Temozolomide—Headache—Epirubicin—ovarian cancer	1.54e-05	0.000171	CcSEcCtD
Temozolomide—Dizziness—Doxorubicin—ovarian cancer	1.5e-05	0.000167	CcSEcCtD
Temozolomide—Nausea—Epirubicin—ovarian cancer	1.46e-05	0.000162	CcSEcCtD
Temozolomide—Vomiting—Doxorubicin—ovarian cancer	1.45e-05	0.00016	CcSEcCtD
Temozolomide—Rash—Doxorubicin—ovarian cancer	1.43e-05	0.000159	CcSEcCtD
Temozolomide—Dermatitis—Doxorubicin—ovarian cancer	1.43e-05	0.000159	CcSEcCtD
Temozolomide—Headache—Doxorubicin—ovarian cancer	1.42e-05	0.000158	CcSEcCtD
Temozolomide—Nausea—Doxorubicin—ovarian cancer	1.35e-05	0.00015	CcSEcCtD
